» Articles » PMID: 22753356

Oncogenic Potential is Related to Activating Effect of Cancer Single and Double Somatic Mutations in Receptor Tyrosine Kinases

Overview
Journal Hum Mutat
Specialty Genetics
Date 2012 Jul 4
PMID 22753356
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant activation of receptor tyrosine kinases (RTKs) is a common feature of many cancer cells. It was previously suggested that the mechanisms of kinase activation in cancer might be linked to transitions between active and inactive states. Here, we estimate the effects of single and double cancer mutations on the stability of active and inactive states of the kinase domains from different RTKs. We show that singleton cancer mutations destabilize active and inactive states; however, inactive states are destabilized more than the active ones, leading to kinase activation. We show that there exists a relationship between the estimate of oncogenic potential of cancer mutation and kinase activation. Namely, more frequent mutations have a higher activating effect, which might allow us to predict the activating effect of the mutations from the mutation spectra. Independent evolutionary analysis of mutation spectra complements this observation and finds the same frequency threshold defining mutation hotspots. We analyze double mutations and report a positive epistasis and additional advantage of doublets with respect to cancer cell fitness. The activation mechanisms of double mutations differ from those of single mutations and double mutation spectrum is found to be dissimilar to the mutation spectrum of singletons.

Citing Articles

Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations.

Yan F, Liu X, Zhang S, Su J, Zhang Q, Chen J RSC Adv. 2022; 8(70):39797-39810.

PMID: 35558225 PMC: 9091310. DOI: 10.1039/c8ra06844e.


Applying Bioinformatic Platforms, In Vitro, and In Vivo Functional Assays in the Characterization of Genetic Variants in the GH/IGF Pathway Affecting Growth and Development.

Domene S, Scaglia P, Gutierrez M, Domene H Cells. 2021; 10(8).

PMID: 34440832 PMC: 8392544. DOI: 10.3390/cells10082063.


PremPS: Predicting the impact of missense mutations on protein stability.

Chen Y, Lu H, Zhang N, Zhu Z, Wang S, Li M PLoS Comput Biol. 2020; 16(12):e1008543.

PMID: 33378330 PMC: 7802934. DOI: 10.1371/journal.pcbi.1008543.


Limitations and challenges in protein stability prediction upon genome variations: towards future applications in precision medicine.

Sanavia T, Birolo G, Montanucci L, Turina P, Capriotti E, Fariselli P Comput Struct Biotechnol J. 2020; 18:1968-1979.

PMID: 32774791 PMC: 7397395. DOI: 10.1016/j.csbj.2020.07.011.


Computational Approaches to Prioritize Cancer Driver Missense Mutations.

Zhao F, Zheng L, Goncearenco A, Panchenko A, Li M Int J Mol Sci. 2018; 19(7).

PMID: 30037003 PMC: 6073793. DOI: 10.3390/ijms19072113.


References
1.
Matsuda T, Bebenek K, Masutani C, Rogozin I, Hanaoka F, Kunkel T . Error rate and specificity of human and murine DNA polymerase eta. J Mol Biol. 2001; 312(2):335-46. DOI: 10.1006/jmbi.2001.4937. View

2.
Glazko G, Babenko V, Koonin E, Rogozin I . Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection. Biol Direct. 2006; 1:4. PMC: 1403748. DOI: 10.1186/1745-6150-1-4. View

3.
Zhang X, Gureasko J, Shen K, Cole P, Kuriyan J . An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006; 125(6):1137-49. DOI: 10.1016/j.cell.2006.05.013. View

4.
Dixit A, Verkhivker G . Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol. 2009; 5(8):e1000487. PMC: 2722018. DOI: 10.1371/journal.pcbi.1000487. View

5.
Tam I, Leung E, Tin V, Chua D, Sihoe A, Cheng L . Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009; 8(8):2142-51. DOI: 10.1158/1535-7163.MCT-08-1219. View